Piramal Pharma Reports Q2 Profit, Raises FY27 Revenue Guidance Amid Supply Chain Diversification
Piramal Pharma reported a consolidated net profit of Rs 5 crore in Q2 FY27, reversing previous losses, driven by 28% revenue growth and a 72% rise in EBITDA. The company raised its FY27 revenue growth guidance to 19-20%, expecting stronger second-half performance supported by its CDMO business and new product pipelines. It has reduced reliance on Chinese raw materials to under 10% to mitigate supply-chain risks. Analysts have upgraded the stock, citing improved operational execution and growth prospects.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (70/100). Lens Score 35/100.
Outlets measured: moneycontrol, thefinancialexpress, moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 28 Oct, 12:46 pm. Other outlets followed.